Meeting
2019 ASCO Annual Meeting
PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.
Authors
Javier Pascual
Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
Javier Pascual , Iain R. MacPherson , Anne Caroline Armstrong , Sarah Emily Ward , Mona Parmar , Alison Joanne Turner , Hannah Bye , Paula Proszek , Andrew Dodson , Isaac Garcia-Murillas , Jenny King , Emma Hall , Laura Finneran , Juanita Suzanne Lopez , Alicia Frances Clare Okines , Alistair E. Ring , Nicholas C. Turner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02389842
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1051)
DOI
10.1200/JCO.2019.37.15_suppl.1051
Abstract #
1051
Poster Bd #
132
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.
First Author: Juanita Suzanne Lopez
Poster
2014 Breast Cancer Symposium
Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
First Author: Pamela N. Munster
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
Poster
2021 ASCO Annual Meeting
The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
First Author: Kelvin K H Bao